UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

     CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 2003

Shire Pharmaceuticals Group plc
(Exact name of registrant as specified in its charter)
England and Wales
(State or other jurisdiction of incorporation)
0-29630 (Commission File Number)	98-0359573 (IRS Employer Identification No.)
Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England
(Address of principal executive offices)	(Zip code)
Registrant's telephone number, including area code	44 1256 894 000
(Former name or former address, if changed since last report)

Item 5.  Other Events

     Shire Pharmaceuticals Group plc has issued the press releases attached as Exhibits 99.1 and 99.2 and which are incorporated by reference herein.

Item 7.  Financial Statements and Exhibits

	(c)   Exhibits. The following exhibits are filed herewith:
99.1	Press Release dated October 16, 2003

99.2 Press Release dated October 20, 2003

-2-

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 21, 2003	SHIRE PHARMACEUTICALS GROUP PLC
	By:	/s/ A C Russell
		Name: Angus Russell
		Title: Group Finance Director

EXHIBIT INDEX

Number	Description
99.1	Press Release dated October 16, 2003
99.2	Press Release dated October 20, 2003